Exelixis looks cheaper on one of the three valuation measures in this snapshot, while ICON has the lower PEG and price-to-book ratios. The results are mixed, so neither company stands out as the clear value pick across the board.
Exelixis Inc. and ICON PLC are both in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry group. On November 3, 2026, their latest adjusted closes were US$72.31 for Exelixis and US$203.77 for ICON. Share prices alone don’t show which stock offers better value. Based on the multiples provided, Exelixis has the lower P/E, while ICON has the lower PEG and P/B. The differences between those measures matter more than the share prices themselves. See our pages for Exelixis and ICON.
Investor takeaway: The comparison is split: Exelixis has the lower P/E, while ICON has the lower PEG and P/B. Each measure reflects a different aspect of valuation, and none tells you on its own which company is the better investment. The snapshot also shows a wide gap in trailing return on equity, but that figure alone doesn’t explain either company’s prospects or risks.
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Exelixis Inc
EXEL.US
Health Care
$72.31
$17.64B
1D
+3.11%
1W
+10.65%
ICON PLC
ICLR.US
Health Care
$203.77
$15.27B
1D
-0.67%
1W
+11.36%
The valuation measures point in different directions
Exelixis has a P/E of 21.6, compared with 82.2 for ICON. ICON’s PEG is 0.57, versus 2.56 for Exelixis, and its P/B is 1.67, versus 9.65. ICON therefore looks cheaper on two of the three measures provided. That doesn’t prove it’s undervalued, safer, or likely to outperform. Multiples can reflect different expectations and circumstances for each company.
Bull case
Exelixis, the company with the lower P/E, also reports a TTM ROE of 44.3%. Investors comparing its earnings multiple with its reported profitability may find that figure useful. But it doesn’t establish that the shares are undervalued.
Bear case
Exelixis has the higher PEG and P/B in this comparison, so its lower P/E doesn’t make it cheaper by every measure. Its reported analyst target of US$61.36 is also below its latest close. Analyst targets are estimates, not guarantees.
A split verdict across the multiples
Exelixis has a P/E of 21.6, compared with 82.2 for ICON, making Exelixis cheaper on that measure. The other two measures favour ICON: its PEG is 0.57, versus 2.56 for Exelixis, and its P/B is 1.67, versus 9.65. So ICON looks cheaper on two of the three measures in this snapshot. That’s a relative comparison, not proof that either stock is mispriced. Each multiple has limitations, and the figures don’t show the assumptions behind earnings growth or the companies’ balance sheets.
Profitability, size and analyst estimates add context
Exelixis has a market cap of US$17.6B and a TTM ROE of 44.3%. ICON’s market cap is US$15.3B, and its TTM ROE is 4.7%. Both companies have a reported dividend yield of 0.00%, and both have a Buy analyst consensus label. The analyst targets are US$61.36 for Exelixis and US$231.29 for ICON, compared with latest adjusted closes of US$72.31 and US$203.77, respectively. These figures are a snapshot, not a promise of future returns. If you’re comparing the two, look beyond the multiples and consider each company’s outlook, risks and financial results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
